[Thalidomide in the treatment of chronic lupus erythematosus].
The effect of thalidomide was investigated in 12 patients with chronic lupus erythematosus resistant to classical treatment (antimalarial drugs, topical steroids). 10 patients were improved and 2 were not sensitive to the treatment. The doses were 100 mg/day for a minimum period of 2 months. With the exception of 1 case, the treatment was well tolerated. The indications of thalidomide in dermatology and the mechanism of action of the drug are briefly discussed.
D000328:Adult; D000368:Aged; D055598:Chemical Phenomena; D002621:Chemistry; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013792:Thalidomide / Q000494:pharmacology / Q000627:therapeutic use*
D013792:Thalidomide
La thalidomide dans le traitement du lupus érythémateux chronique.